Hyperhidrosis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

  • ID: 4451350
  • Report
  • 55 pages
  • P&S Market Research
1 of 3
Hyperhidrosis currently exhibits a growing pipeline with 12 drug candidates.

Hyperhidrosis therapeutics pipeline in 2017

The study analyzed that the hyperhidrosis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Insights on pipeline segments

Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrronium tosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline drug candidates are being developed using the topical route of administration.

Cholinergic Receptor, a major target in Hyperhidrosis Therapeutics Pipeline

Major players in the market are putting more emphasis on targeting cholinergic receptors. The drug candidates used for the treatment of hyperhidrosis, act on cholinergic receptors and block its activity that interfere with sweating. For instance, Glycopyrronium tosylate, a Phase III drug candidate by Dermira, Inc. acts topically and blocks the cholinergic receptor.

Various collaborations for hyperhidrosis drug development

In March 2015, Kaken Pharmaceutical Co., Ltd. and Brickell Biotech, Inc. entered in an agreement concerning the exclusive licensing and joint development of BBI-4000. Under the terms of agreement Brickell Biotech, Inc. agreed to conduct a Phase IIb clinical trial of BBI-4000 in the U.S. for patients with primary focal hyperhidrosis..

Some of the key players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan plc, TheraVida Inc. and others.

Hyperhidrosis Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Hyperhidrosis Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Hyperhidrosis Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.4 Inactive Drug Candidates
5.5 Discontinued Drug Candidates

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Hyperhidrosis Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Hyperhidrosis Therapeutics Pipeline

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Hyperhidrosis Therapeutics Pipeline
7.2 SWOT Analysis Hyperhidrosis Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Hyperhidrosis Therapeutics, By Company (2017)
Description Of Phase III Drug Candidates
Clinical Trials Of Phase III Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Inactive Hyperhidrosis Pipeline Drug Candidates
Discontinued Hyperhidrosis Pipeline Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Hyperhidrosis Therapeutics Drug Candidates Under Development (2017)
Hyperhidrosis Pipeline Split, By Molecule Type (2017)
Hyperhidrosis Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll